相似图钉
礼来2026年第三季度财报电话会议
预估可信度 71%36天后礼来尚未确认日期（截至2026年9月22日，没有发布“礼来确认2026年第三季度业绩发布日期及电话会议”的公告；第二季度的公告于7月22日发布，定于8月5日）。Public.com[2]和Nasdaq[3]将第三季度财报列为“预计”于2026年10月29日“开盘前”发布，这与礼来一贯的节奏（2025年第三季度于2025年10月30日公布）以及其电话会议“将于美东时间上午10点开始”的惯例相符——因此定为2026年10月29日10:00 ET（14:00 UTC），在礼来发布确认公告前均为估计时间。礼来预计将于10月29日公布2026年第三季度业绩，并照例在美东时间上午10点召开电话会议。此前第二季度营收在Mounjaro和Zepbound带动下增长48%至230亿美元，公司将2026年全年营收指引上调至850亿至870亿美元。0.71- 0.65
Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
已确认可信度 88%23天前The release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".[1]Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.$2.9B0.65Elecoglipron's Phase 3 Trial in Type 2 Diabetes Mellitus Reads Out
预估可信度 50%1.8年后ClinicalTrials.gov[1] lists 2028-07-05 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.0.64Lilly Submits Retatrutide to the FDA for Approval
预估延期3个月可信度 77%189天后Lilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.[1]Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.0.62- $6.5B0.61
Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
已确认可信度 87%120天前Lilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".[1]Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.$3.8B0.61Maridebart Cafraglutide's Phase 3 Trial in Heart Failure With Preserved Ejection Fraction Reads Out
预估可信度 50%1.8年后ClinicalTrials.gov[1] lists 2028-06-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Amgen's phase 3 trial of Maridebart Cafraglutide in heart failure with preserved ejection fraction reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,056 participants. This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.0.61Elecoglipron's Phase 3 Trial in Weight Management Reads Out
预估可信度 50%1.9年后ClinicalTrials.gov[1] lists 2028-07-31 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Elecoglipron in weight management reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,500 participants. This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).0.60TSMC's Dresden Fab (ESMC) Starts Production
预估可信度 73%1.3年后TSMC's[1][6] founding release gives a bound, not a day: "production targeted to begin by the end of 2027"; at the September 2026 topping-out the partners still said production starts in 2027 and Hardwareluxx[3] reported tool installation "bis Ende 2027", after which the first chips follow - so 31 December 2027, estimated.ESMC, TSMC's EUR 10 billion joint venture with Bosch, Infineon and NXP, is due to start production at its Dresden fab by the end of 2027 - Europe's first FinFET-capable foundry, making 28/22nm and 16/12nm chips mainly for cars and industry.€10B0.60TSMC's Dresden Fab (ESMC) Tops Out
已确认可信度 80%9天前Focus Taiwan[1]: "A topping out ceremony was held Monday at the site" (dateline Sept. 14, "The ceremony, held on Sept. 14"); dpa's preview gave the time: ESMC "feiert ... am Montag (12.00 Uhr) mit einem Richtfest den Abschluss des Rohbaus" - noon CEST, 10:00 UTC.Twenty-five months after its groundbreaking, ESMC - TSMC's joint venture with Bosch, Infineon and NXP - celebrated the topping-out of its roughly EUR 10 billion chip fab in Dresden, TSMC's first in Europe. The shell is finished; cleanroom fit-out follows, with the first process tools due in the second half of 2027.€10B0.60TSMC Starts Volume Production of 2nm (N2) Chips in Kaohsiung
预估可信度 73%266天前TSMC's[1][2] 2nm page says N2 "has started volume production in 4Q25 as planned" and its 2025 annual report that it "entered high volume manufacturing in 4Q'25"; neither names the day, so the quarter's last day stands in.TSMC's first nanosheet-transistor node, N2, entered volume production in the fourth quarter of 2025 as planned, starting at Fab 22 in Kaohsiung, with Fab 20 in Hsinchu as its second 2nm fab.0.59